Targeted ALK inhibition achieving tumour control in metastatic melanoma: a case report

Authors

  • Cornelia Schuster Department of Oncology, Haukeland University Hospital, Bergen, Norway https://orcid.org/0000-0003-2665-9527
  • Irja Alida Oppedal Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway
  • Liv Iren Vinnem Department of Oncology, Haukeland University Hospital, Bergen, Norway https://orcid.org/0009-0005-9516-2225
  • Eirin Lunden Abrahamsson Cancer Genomics, Haukeland University Hospital, Bergen, Norway
  • Torill Myklestad Barrett Department of Pathology, Haukeland University Hospital, Bergen, Norway
  • Eli Sihn Samdal Steinskog Department of Oncology, Haukeland University Hospital, Bergen, Norway
  • Hege Elisabeth Giercksky Russnes Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital, Oslo, Norway; Division of Cancer Medicine, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway https://orcid.org/0000-0001-8724-1891
  • Åslaug Helland Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway https://orcid.org/0000-0002-5520-0275

DOI:

https://doi.org/10.2340/1651-226X.2026.46424

Keywords:

Cutanteous melanoma, liver metastasis, molecular targeted therapy, eml4 alk fusion protein

Downloads

Download data is not yet available.

References

Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158–66. DOI: https://doi.org/10.1200/JCO.2000.18.1.158

Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol. 2024;35:1191–9. DOI: https://doi.org/10.1016/j.annonc.2024.08.2330

Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1): 11–22. DOI: https://doi.org/10.1056/NEJMoa2407417

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46. DOI: https://doi.org/10.1056/NEJMoa1910836

Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20:1239–51. DOI: https://doi.org/10.1016/S1470-2045(19)30388-2

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877–88. DOI: https://doi.org/10.1056/NEJMoa1406037

Darabi S, Elliott A, Braxton DR, Zeng J, Hodges K, Poorman K, et al. Transcriptional profiling of malignant melanoma reveals novel and potentially targetable gene fusions. Cancers (Basel). 2022;14(6):1505. DOI: https://doi.org/10.3390/cancers14061505

Lenskaya V, Erikson L, Prieto VG, Cho WC. Gene fusions in melanocytic lesions: an updated comprehensive review. J Pathol Transl Med. 2026;60:285–306. DOI: https://doi.org/10.4132/jptm.2026.03.11

Puco K, Fagereng GL, Brabrand S, Niehusmann P, Store Blix E, Samdal Steinskog ES, et al. IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results. Acta Oncol. 2024;63:379–84. DOI: https://doi.org/10.2340/1651-226X.2024.28322

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. DOI: https://doi.org/10.1016/j.ejca.2008.10.026

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–38. DOI: https://doi.org/10.1056/NEJMoa1704795

Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, et al. Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med. 2024;390:1265–76. DOI: https://doi.org/10.1056/NEJMoa2310532

Couts KL, Bemis J, Turner JA, Bagby SM, Murphy D, Christiansen J, et al. ALK inhibitor response in melanomas expressing EML4-ALK fusions and alternate ALK isoforms. Mol Cancer Ther. 2018;17:222–31. DOI: https://doi.org/10.1158/1535-7163.MCT-17-0472

Daruish M, Ambrogio F, Colagrande A, Marzullo A, Alaggio R, Trilli I, et al. Kinase fusions in spitz melanocytic tumors: the past, the present, and the future. Dermatopathology (Basel). 2024;11:112–23. DOI: https://doi.org/10.3390/dermatopathology11010010

Lin L, van der Noort V, Steeghs N, Ruiter G, Beijnen JH, Huitema ADR. A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure-response relationships: a proof-of-concept study with alectinib. Cancer Chemother Pharmacol. 2024;94:453–9. DOI: https://doi.org/10.1007/s00280-024-04698-w

Smolle E, Taucher V, Lindenmann J, Jost PJ, Pichler M. Current knowledge about mechanisms of drug resistance against ALK inhibitors in non-small cell lung cancer. Cancers. 2021;13(4):699. DOI: https://doi.org/10.3390/cancers13040699

Sukniam K, Manaise HK, Popp K, Popp R, Gabriel E. Role of surgery in metastatic melanoma and review of melanoma molecular characteristics. Cells. 2024;13(6):465. DOI: https://doi.org/10.3390/cells13060465

Downloads

Published

2026-10-01

How to Cite

Schuster, C., Oppedal , I. A., Vinnem, L. I., Abrahamsson, E. L., Barrett, T. M., Steinskog, E. S. S., … Helland, Åslaug. (2026). Targeted ALK inhibition achieving tumour control in metastatic melanoma: a case report. Acta Oncologica, 65, 814–817. https://doi.org/10.2340/1651-226X.2026.46424

Issue

Vol. 65 (2026): Acta Oncologica

Section

Letter

Categories

License

Copyright (c) 2026 Cornelia Schuster, Irja Alida Oppedal , Liv Iren Vinnem, Eirin Lunden Abrahamsson, Torill Myklestad Barrett, Eli Sihn Samdal Steinskog, Hege Elisabeth Giercksky Russnes , Åslaug Helland

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.